Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · Real-Time Price · USD

30.39

+1.07 (3.65%)

At close: Mar 4, 2026, 4:00 PM EST

30.22

-0.17 (-0.56%)

After-hours: Mar 4, 2026, 5:55 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Discovering, Developing and Commercializing Potential Best-In-Class Medicines for Serious and Rare Diseases	70.85M	302.00K	314.00K	1.77M	2.96M
Discovering, Developing and Commercializing Potential Best-In-Class Medicines for Serious and Rare Diseases Growth	23359.93%	-3.82%	-82.28%	-40.20%	182.19%
Total	70.85M	302.00K	314.00K	1.77M	2.96M
Total Growth	23359.93%	-3.82%	-82.28%	-40.20%	182.19%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	70.85M	302.00K	314.00K	1.77M	2.96M
United States Growth	23359.93%	-3.82%	-82.28%	-40.20%	182.19%
Total	70.85M	302.00K	314.00K	1.77M	2.96M
Total Growth	23359.93%	-3.82%	-82.28%	-40.20%	182.19%

Source: S&P Global Market Intelligence.